13.2 C
London

Elliot Fraser

business journalist, renowned for his columns in the Financial Times

PowerBank and Intellistake Strategic Alliance: Pioneering Bitcoin Treasuries and RWA Tokenisation

The PowerBank and Intellistake Strategic Alliance represents a decisive step toward integrating digital currencies into corporate energy and financial strategies. It signals a broader shift where traditional infrastructure meets the emerging world of tokenised finance. A New Era in Digital...

Corpay to Acquire Alpha Group: Expanding Cross-Border FX for Institutional Growth

Corpay to Acquire Alpha Group in a strategic move aimed at consolidating its presence in the B2B cross-border foreign exchange sector. This acquisition marks a significant milestone for Corpay as it accelerates its entry into the investment fund segment—a...

Nvidia Resumes Sales of Advanced AI Chips in China: A Strategic Reopening

Nvidia resumes sales of advanced AI chips in China, marking a significant step in the company’s efforts to maintain its dominance in the lucrative AI semiconductor market. The announcement, made Tuesday, comes just ahead of CEO Jensen Huang’s visit...

Alstom New York contract: official details and strategic blind spots

The Alstom New York contract has now moved from headline to substance. The French rail giant has disclosed the specifics of its multi-billion-euro agreement with New York’s Metropolitan Transportation Authority (MTA). Valued at €2 billion ($2.3 billion), the deal...

Olo acquired by Thoma Bravo: a $2 billion strategic shift for restaurant technology

The announcement that Olo acquired by Thoma Bravo marks a pivotal development in the restaurant technology landscape. Olo Inc. (NYSE: OLO), a prominent open SaaS platform serving leading restaurant brands, has entered into a definitive agreement to be acquired...

Klotho Neurosciences ALS Gene Therapy Progresses Toward Clinical Stage

Klotho Neurosciences ALS gene therapy KLTO-202 is advancing through a critical phase of manufacturing and process development, positioning the company for early-stage clinical trials by Q3 2026. This significant milestone reflects Klotho Neurosciences, Inc. (NASDAQ: KLTO)'s ongoing commitment to...
spot_img

latest articles